This study focuses on patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH), a condition where blood clots cause high blood pressure in the lungs’ arteries. The study examines the effects of stopping treatment with riociguat, a medication that helps widen blood vessels in the lungs, after patients have undergone a procedure called balloon pulmonary angioplasty that opens up narrowed blood vessels.
The purpose of this research is to determine if it is safe to stop taking riociguat in patients whose blood pressure in the lungs has improved after the balloon procedure. The medication is given as film-coated tablets, with patients taking up to 7.5 milligrams per day. Some patients will continue taking riociguat, while others will stop the medication.
The study will last 16 weeks, during which doctors will monitor the blood pressure in patients’ lungs and other health measures. Throughout the study, various tests will be performed to check how well the heart and lungs are working, including measurements of exercise capacity and quality of life. This will help determine if stopping the medication is a safe option for patients who have shown improvement after their procedure.



The Netherlands